Kratom and 7-OH Dependence Rise in US Treatment Centers

Addiction treatment centers across the United States are reporting a rise in patients who have become dependent on kratom, a tropical plant whose leaves are chewed or brewed for their stimulant and opioid‑like effects, and on 7‑OH, a more potent metabolite produced when the body processes kratom. The surge has prompted clinicians to adjust their screening protocols and expand counseling resources to address the unique withdrawal patterns associated with these substances.

The Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) have issued warnings about kratom’s safety profile, noting that 7‑OH can produce stronger euphoric and analgesic effects than kratom itself. As a result, treatment facilities are encountering patients who exhibit higher tolerance levels, more pronounced cravings, and a greater risk of relapse. Many centers are now incorporating targeted pharmacologic support and specialized behavioral therapies to manage the complex withdrawal symptoms that arise from both kratom and its metabolite.

In response to the growing trend, several treatment programs are collaborating with researchers to better understand the pharmacodynamics of 7‑OH and to develop evidence‑based protocols for detoxification and recovery. While the long‑term outcomes of these interventions remain under study, the increased attention from healthcare providers and regulatory agencies underscores the need for continued surveillance and education about the risks associated with kratom and its derivatives.